Vitamin D receptor agonists, cancer and the immune system: An intricate relationship

Current Topics in Medicinal Chemistry

Volumn 6, Issue 12, 2006, Pages 1297-1301

  Adorini, Luciano ^a   Daniel, Kenn C ^a   Penna, Giuseppe ^a  

^a BioXell SpA   (Italy)

Author keywords

Calcitriol; Real time RT PCR; Retinoid X receptor (RXR); Superficial bladder cancer

Indexed keywords

BXL 628; CALCITRIOL; CALCITRIOL DERIVATIVE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FINASTERIDE; GEMCITABINE; MITOMYCIN C; OXYGENASE; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR AGONIST;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER CELL; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG POTENTIATION; DRUG TOLERANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; NONHUMAN; PROSTATE HYPERTROPHY; REVIEW; TREATMENT INDICATION;

CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DOXORUBICIN; DRUG SYNERGISM; EPIRUBICIN; HUMANS; MOLECULAR STRUCTURE; RECEPTORS, CALCITRIOL; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY BLADDER NEOPLASMS;

EID: 33746374780     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606777864890     Document Type: Review

References (48)

1. Deluca, H.F.; Cantorna, M.T. Vitamin D: its role and uses in immunology. FASEB J, 2001, 15, 2579.
2. Mathieu, C.; Adorini, L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med, 2002, 8, 174.
3. Adorini, L. 1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr. Opin. Investig. Drugs, 2002, 3, 1458.
4. Griffin, M.D.; Xing, N.; Kumar, R. Vitamin D and its Analogs as Regulators of Immune Activation and Antigen Presentation. Annu. Rev. Nutr., 2003,
5. Pinette, K.V.; Yee, Y.K.; Amegadzie, B.Y.; Nagpal, S. Vitamin D receptor as a drug discovery target. Mini Rev. Med. Chem, 2003, 3, 193.
6. Norman, A.W.; Mizwicki, M.T.; Okamura, W.H. Ligand structure-function relationships in the vitamin D endocrine system from the perspective of drug development (including cancer treatment). Recent Results Cancer Res., 2003, 164, 55.
7. Haussler, M.R.; Whitfield, G.K.; Haussler, C.A.; Hsieh, J.C.; Thompson, P.D.; Selznick, S.H.; Dominguez, C.E.; Jurutka, P.W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner Res., 1998, 13, 325.
8. Carlberg, C.; Polly, P. Gene regulation by vitamin D3. Crit. Rev. Eukaryot. Gene Expr., 1998, 8, 19.
9. Holick, M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr., 2004, 79, 362.
10. Giovannucci, E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control, 2005, 16, 83.
11. Schwartz, G.G. Vitamin D and the epidemiology of prostate cancer. Semin Dial, 2005, 18, 276.
12. Trump, D.L.; Hershberger, P.A.; Bernardi, R.J.; Ahmed, S.; Muindi, J.; Fakih, M.; Yu, W.D.; Johnson, C.S. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol., 2004, 89-90, 519.
13. Nagpal, S.; Na, S.; Rathnachalam, R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev., 2005, 26, 662.
14. Bouillon, R.; Moody, T.; Sporn, M.; Barrett, J.C.; Norman, A.W. NIH deltanoids meeting on Vitamin D and cancer Conclusion and strategic options. J. Steroid Biochem. Mol. Biol., 2005, 97, 3.
15. Beer, T.M.; Myrthue, A. Calcitriol in cancer treatment: from the lab to the clinic. Mol. Cancer Ther., 2004, 3, 373.
16. Guyton, K.Z; Kensler, T.W.; Posner, G.H. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr. Rev., 2003, 61, 227.
17. Krishnan, A.V.; Peehl, D.M.; Feldman, D. The role of vitamin D in prostate cancer. Recent Results Cancer Res., 2003, 164, 205.
18. Blattman, J.N.; Greenberg, P.D. Cancer immunotherapy: a treatment for the masses. Science, 2004, 305, 200.
19. Pardoll, D.; Allison, J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat. Med., 2004, 10, 887.
20. den Brok, M.H.; Nierkens, S.; Figdor, C.G.; Ruers, T.J.; Adema, G.J. Dendritic cells: tools and targets for antitumor vaccination. Expert Rev. Vaccines, 2005, 4, 699.
21. Banchereau, J.; Palucka, A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol., 2005, 5, 296.
22. Wang, H.; Rayburn, E.; Zhang, R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr. Pharm. Des., 2005, 11, 2889.
23. Schirrmacher, V. T cell-mediated immunotherapy of metastases: state of the art in 2005. Expert Opin. Biol. Ther., 2005, 5, 1051.
24. Shimizu J.; Yamazaki, S.; Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol., 1999, 163, 5211.
25. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer, 2004, 4, 540.
26. 3-mediated effects. J. Immunol., 1998, 160, 209.
27. 3: a transcriptional modulator of the IFN-γ gene. Eur. J. Immunol., 1998, 28, 3017.
28. Adorini, L.; Giarratana, N.; Penna, G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol., 2004, 16, 127.
29. Figdor, C.G.; de Vries, I.J.; Lesterhuis, W.J.; Melief, C.J. Dendritic cell immunotherapy: mapping the way. Nat. Med, 2004, 10, 475.
30. Paczesny, S.; Shi, H.; Saito, H.; Mannoni, P.; Fay, J.; Banchereau, J.; Palucka, A.K. Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccines with a tumor inhibition assay in vitro. J. Immunother., 2005, 28, 148.
31. Giarratana, N.; Penna, G.; Amuchastegui, S.; Mariani, R.; Daniel, K.C.; Adorini, L. A Vitamin D Analog Downregulates Proinflammatory Chemokine Production by Pancreatic Islets Inhibiting T Cell Recruitment and Type 1 Diabetes Development. J. Immunol., 2004, 173, 2280.
32. Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J.R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M.L.; Knutson, K.L.; Chen, L.; Zou, W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med, 2004, 10, 942.
33. Bouillon, R.; Verlinden, L.; Eelen, G.; De Clercq, P.; Vandewalle, M.; Mathieu, C.; Verstuyf, A. Mechanisms for the selective action of Vitamin D analogs. J. Steroid Biochem. Mol. Biol., 2005, 97, 21.
34. Lee, K.L.; Peehl, D.M. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J. Urol., 2004, 172, 1784.
35. Schulman, C.; Lunenfeld, B. The ageing male. World J. Urol., 2002, 20, 4.
36. Peehl, D.M.; Skowronski, R.J.; Leung, G.K.; Wong, S.T.; Stamey, T.A.; Feldman, D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res., 1994, 54, 805.
37. Crescioli, C.; Villari, D.; Forti, G.; Ferruzzi, P.; Petrone, L.; Vannelli, G.B.; Adorini, L.; Salerno, R.; Serio, M.; Maggi, M. Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Mol. Cell Endocrinol., 2002, 198, 69.
38. Crescioli, C.; Ferruzzi, P.; Caporali, A.; Mancina, R.; Comerci, A.; Muratori, M.; Scaltriti, M.; Vannelli, G.B.; Smiroldo, S.; Mariani, R.; Villari, D.; Bettuzzi, S.; Serio, M.; Adorini, L.; Maggi, M. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology, 2003, 144, 3046.
39. Crescioli, C.; Ferruzzi, P.; Caporali, A.; Scaltriti, M.; Bettuzzi, S.; Mancina, R.; Gelmini, S.; Serio, M.; Villari, D.; Vannelli, G.B.; Colli, E.; Adorini, L.; Maggi, M. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol., 2004, 150, 591.
40. Colli, E. BXL628, a novel vitamin D analog arrests prostate growth in aptients with benign prostatic hyperplasia: a randomized clinical trial. Eur. Urol., 2006,
41. Crescioli, C.; Maggi, M.; Luconi, M.; Vannelli, G.B.; Salerno, R.; Sinisi, A.A.; Bonaccorsi, L.; Ferruzzi, P.; Barni, T.; Forti, G.; Serio, M. Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate, 2002, 50, 15.
42. Strother, J.M.; Beer, T.M.; Dreicer, R. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005? Eur. J. Cancer, 2005, 41, 954.
43. Malmstrom, P.U. Advances in intravesical therapy of urinary bladder cancer. Expert Rev. Anticancer Ther., 2004, 4, 1057.
44. Konety, B.R.; Lavelle, J.P.; Pirtskalaishvili, G.; Dhir, R.; Meyers, S.A.; Nguyen, T.S.; Hershberger, P.; Shurin, M.R.; Johnson, C.S.; Trump, D.L.; Zeidel, M.L.; Getzenberg, R.H. Effects of vitamin D (catcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J. Urol., 2001, 165, 253.
45. Chou, T.C.; Tatalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme. Regul., 1984, 22, 27.
46. Mitsumori, K.; Tsuchiya, N.; Habuchi, T.; Li, Z.; Akao, T.; Ohyama, C.; Sato, K.; Kato, T. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection. BJU Int., 2004, 94, 317.
47. Siwinska, A.; Opolski, A.; Chrobak, A.; Wietrzyk, J.; Wojdat, E.; Kutner, A.; Szelejewski, W.; Radzikowski, C. Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res., 2001, 21, 1925.
48. Ravid, A.; Rocker, D.; Machlenkin, A.; Rotem, C.; Hochman, A.; Kessler-Icekson, G.; Liberman, U.A.; Koren, R. 1,25-Dihydroxy-vitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res., 1999, 59, 862.